{"pmid":32473070,"title":"Treatment of COVID-19 with pentoxifylline: Could it be a potential adjuvant therapy?","text":["Treatment of COVID-19 with pentoxifylline: Could it be a potential adjuvant therapy?","The world is facing a viral pandemic of a new coronavirus called COVID-19. Pentoxifylline is a methyl-xanthine and it inhibits phosphodiesterase IV (PDE IV). This drug is known for its unique features as an immunomodulatory and anti-inflammatory agent, also it could have antiviral affects. This is a scoping review, in which all related articles on COVID-19 and the probable benefits of Pentoxifylline against COVID-19 pathogenesis, in Medline, Scopus, Web of Sciences and Google Scholar up to March 20, 2020 with proper keywords including: pentoxifylline, Pentoxil, COVID-19, coronavirus, treatment, anti-inflammatory, immunomodulatory, anti-fibrosis, oxygenation, circulation, bronchodilator, ARDS and organ failure. We found many confirmatory data on proper efficacy of pentoxifylline n controlling COVID-19 and its consequences. The antiviral, anti-inflammatory, anti-oxidative, immune-modulatory, bronchodilator and respiratory supportive effects and protective roles in organ failures of PTX, along with its main functions means better circulation-oxygenation properties, low price and safety, make it a promising drug to be considered for covid-19 treatment, especially as an adjuvant therapy in combination with other drugs. This article is protected by copyright. All rights reserved.","Dermatol Ther","Seirafianpour, Farnoosh","Mozafarpoor, Samaneh","Fattahi, Nima","Sadeghzadeh-Bazargan, Afsaneh","Hanifiha, Melika","Goodarzi, Azadeh","32473070"],"abstract":["The world is facing a viral pandemic of a new coronavirus called COVID-19. Pentoxifylline is a methyl-xanthine and it inhibits phosphodiesterase IV (PDE IV). This drug is known for its unique features as an immunomodulatory and anti-inflammatory agent, also it could have antiviral affects. This is a scoping review, in which all related articles on COVID-19 and the probable benefits of Pentoxifylline against COVID-19 pathogenesis, in Medline, Scopus, Web of Sciences and Google Scholar up to March 20, 2020 with proper keywords including: pentoxifylline, Pentoxil, COVID-19, coronavirus, treatment, anti-inflammatory, immunomodulatory, anti-fibrosis, oxygenation, circulation, bronchodilator, ARDS and organ failure. We found many confirmatory data on proper efficacy of pentoxifylline n controlling COVID-19 and its consequences. The antiviral, anti-inflammatory, anti-oxidative, immune-modulatory, bronchodilator and respiratory supportive effects and protective roles in organ failures of PTX, along with its main functions means better circulation-oxygenation properties, low price and safety, make it a promising drug to be considered for covid-19 treatment, especially as an adjuvant therapy in combination with other drugs. This article is protected by copyright. All rights reserved."],"journal":"Dermatol Ther","authors":["Seirafianpour, Farnoosh","Mozafarpoor, Samaneh","Fattahi, Nima","Sadeghzadeh-Bazargan, Afsaneh","Hanifiha, Melika","Goodarzi, Azadeh"],"date":"2020-05-31T11:00:00Z","year":2020,"_id":"32473070","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1111/dth.13733","keywords":["ards (acute respiratory distress syndrome)","covid-19","pentoxil","sars (severe acute respiratory syndrome)","anti-fibrosis","anti-inflammatory","anti-oxidant","apoptosis-regulatory","bronchodilator","coronavirus","immunomodulatory","oxygenation","pentoxifylline","perfusion","review","treatment"],"locations":["Medline","Scopus"],"topics":["Treatment"],"weight":1,"_version_":1668255193285787648,"score":9.490897,"similar":[{"pmid":32471278,"title":"Pulmonary Delivery of Fenretinide: A Possible Adjuvant Treatment In COVID-19.","text":["Pulmonary Delivery of Fenretinide: A Possible Adjuvant Treatment In COVID-19.","At present, there is no vaccine or effective standard treatment for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection (or coronavirus disease-19 (COVID-19)), which frequently leads to lethal pulmonary inflammatory responses. COVID-19 pathology is characterized by extreme inflammation and amplified immune response with activation of a cytokine storm. A subsequent progression to acute lung injury (ALI) or acute respiratory distress syndrome (ARDS) can take place, which is often followed by death. The causes of these strong inflammatory responses in SARS-CoV-2 infection are still unknown. As uncontrolled pulmonary inflammation is likely the main cause of death in SARS-CoV-2 infection, anti-inflammatory therapeutic interventions are particularly important. Fenretinide N-(4-hydroxyphenyl) retinamide is a bioactive molecule characterized by poly-pharmacological properties and a low toxicity profile. Fenretinide is endowed with antitumor, anti-inflammatory, antiviral, and immunomodulating properties other than efficacy in obesity/diabetic pathologies. Its anti-inflammatory and antiviral activities, in particular, could likely have utility in multimodal therapies for the treatment of ALI/ARDS in COVID-19 patients. Moreover, fenretinide administration by pulmonary delivery systems could further increase its therapeutic value by carrying high drug concentrations to the lungs and triggering a rapid onset of activity. This is particularly important in SARS-CoV-2 infection, where only a narrow time window exists for therapeutic intervention.","Int J Mol Sci","Orienti, Isabella","Gentilomi, Giovanna Angela","Farruggia, Giovanna","32471278"],"abstract":["At present, there is no vaccine or effective standard treatment for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection (or coronavirus disease-19 (COVID-19)), which frequently leads to lethal pulmonary inflammatory responses. COVID-19 pathology is characterized by extreme inflammation and amplified immune response with activation of a cytokine storm. A subsequent progression to acute lung injury (ALI) or acute respiratory distress syndrome (ARDS) can take place, which is often followed by death. The causes of these strong inflammatory responses in SARS-CoV-2 infection are still unknown. As uncontrolled pulmonary inflammation is likely the main cause of death in SARS-CoV-2 infection, anti-inflammatory therapeutic interventions are particularly important. Fenretinide N-(4-hydroxyphenyl) retinamide is a bioactive molecule characterized by poly-pharmacological properties and a low toxicity profile. Fenretinide is endowed with antitumor, anti-inflammatory, antiviral, and immunomodulating properties other than efficacy in obesity/diabetic pathologies. Its anti-inflammatory and antiviral activities, in particular, could likely have utility in multimodal therapies for the treatment of ALI/ARDS in COVID-19 patients. Moreover, fenretinide administration by pulmonary delivery systems could further increase its therapeutic value by carrying high drug concentrations to the lungs and triggering a rapid onset of activity. This is particularly important in SARS-CoV-2 infection, where only a narrow time window exists for therapeutic intervention."],"journal":"Int J Mol Sci","authors":["Orienti, Isabella","Gentilomi, Giovanna Angela","Farruggia, Giovanna"],"date":"2020-05-31T11:00:00Z","year":2020,"_id":"32471278","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.3390/ijms21113812","keywords":["covid-19","adjuvant treatment","anti-inflammatory","antiviral environment","fenretinide","pulmonary delivery"],"topics":["Treatment"],"weight":1,"_version_":1668255193274253313,"score":245.71648},{"pmid":32217117,"pmcid":"PMC7102583","title":"COVID-19: Melatonin as a potential adjuvant treatment.","text":["COVID-19: Melatonin as a potential adjuvant treatment.","This article summarizes the likely benefits of melatonin in the attenuation of COVID-19 based on its putative pathogenesis. The recent outbreak of COVID-19 has become a pandemic with tens of thousands of infected patients. Based on clinical features, pathology, the pathogenesis of acute respiratory disorder induced by either highly homogenous coronaviruses or other pathogens, the evidence suggests that excessive inflammation, oxidation, and an exaggerated immune response very likely contribute to COVID-19 pathology. This leads to a cytokine storm and subsequent progression to acute lung injury (ALI)/acute respiratory distress syndrome (ARDS) and often death. Melatonin, a well-known anti-inflammatory and anti-oxidative molecule, is protective against ALI/ARDS caused by viral and other pathogens. Melatonin is effective in critical care patients by reducing vessel permeability, anxiety, sedation use, and improving sleeping quality, which might also be beneficial for better clinical outcomes for COVID-19 patients. Notably, melatonin has a high safety profile. There is significant data showing that melatonin limits virus-related diseases and would also likely be beneficial in COVID-19 patients. Additional experiments and clinical studies are required to confirm this speculation.","Life Sci","Zhang, Rui","Wang, Xuebin","Ni, Leng","Di, Xiao","Ma, Baitao","Niu, Shuai","Liu, Changwei","Reiter, Russel J","32217117"],"abstract":["This article summarizes the likely benefits of melatonin in the attenuation of COVID-19 based on its putative pathogenesis. The recent outbreak of COVID-19 has become a pandemic with tens of thousands of infected patients. Based on clinical features, pathology, the pathogenesis of acute respiratory disorder induced by either highly homogenous coronaviruses or other pathogens, the evidence suggests that excessive inflammation, oxidation, and an exaggerated immune response very likely contribute to COVID-19 pathology. This leads to a cytokine storm and subsequent progression to acute lung injury (ALI)/acute respiratory distress syndrome (ARDS) and often death. Melatonin, a well-known anti-inflammatory and anti-oxidative molecule, is protective against ALI/ARDS caused by viral and other pathogens. Melatonin is effective in critical care patients by reducing vessel permeability, anxiety, sedation use, and improving sleeping quality, which might also be beneficial for better clinical outcomes for COVID-19 patients. Notably, melatonin has a high safety profile. There is significant data showing that melatonin limits virus-related diseases and would also likely be beneficial in COVID-19 patients. Additional experiments and clinical studies are required to confirm this speculation."],"journal":"Life Sci","authors":["Zhang, Rui","Wang, Xuebin","Ni, Leng","Di, Xiao","Ma, Baitao","Niu, Shuai","Liu, Changwei","Reiter, Russel J"],"date":"2020-03-29T11:00:00Z","year":2020,"_id":"32217117","source":"PubMed","week":"202013|Mar 23 - Mar 29","doi":"10.1016/j.lfs.2020.117583","keywords":["covid-19","cytokines","immunomodulation","melatonin","oxidation-reduction","sars-cov-2"],"e_drugs":["Melatonin"],"topics":["Treatment"],"weight":1,"_version_":1666138492316418048,"score":226.2871},{"pmid":32442105,"title":"The FDA-approved gold drug auranofin inhibits novel coronavirus (SARS-COV-2) replication and attenuates inflammation in human cells.","text":["The FDA-approved gold drug auranofin inhibits novel coronavirus (SARS-COV-2) replication and attenuates inflammation in human cells.","SARS-COV-2 has recently emerged as a new public health threat. Herein, we report that the FDA-approved drug, auranofin, inhibits SARS-COV-2 replication in human cells at low micro molar concentration. Treatment of cells with auranofin resulted in a 95% reduction in the viral RNA at 48 h after infection. Auranofin treatment dramatically reduced the expression of SARS-COV-2-induced cytokines in human cells. These data indicate that auranofin could be a useful drug to limit SARS-CoV-2 infection and associated lung injury due to its antiviral, anti-inflammatory and anti-reactive oxygen species (ROS) properties. Further animal studies are warranted to evaluate the safety and efficacy of auranofin for the management of SARS-COV-2 associated disease.","Virology","Rothan, Hussin A","Stone, Shannon","Natekar, Janhavi","Kumari, Pratima","Arora, Komal","Kumar, Mukesh","32442105"],"abstract":["SARS-COV-2 has recently emerged as a new public health threat. Herein, we report that the FDA-approved drug, auranofin, inhibits SARS-COV-2 replication in human cells at low micro molar concentration. Treatment of cells with auranofin resulted in a 95% reduction in the viral RNA at 48 h after infection. Auranofin treatment dramatically reduced the expression of SARS-COV-2-induced cytokines in human cells. These data indicate that auranofin could be a useful drug to limit SARS-CoV-2 infection and associated lung injury due to its antiviral, anti-inflammatory and anti-reactive oxygen species (ROS) properties. Further animal studies are warranted to evaluate the safety and efficacy of auranofin for the management of SARS-COV-2 associated disease."],"journal":"Virology","authors":["Rothan, Hussin A","Stone, Shannon","Natekar, Janhavi","Kumari, Pratima","Arora, Komal","Kumar, Mukesh"],"date":"2020-05-23T11:00:00Z","year":2020,"_id":"32442105","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.virol.2020.05.002","keywords":["anti-inflammatory","antiviral","auranofin","covid-19","sars-cov-2"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1667523504765927425,"score":223.03477},{"pmid":32418885,"title":"Commentary: Could iron chelators prove to be useful as an adjunct to COVID-19 Treatment Regimens?","text":["Commentary: Could iron chelators prove to be useful as an adjunct to COVID-19 Treatment Regimens?","The pandemic of COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses a significant threat to global health. Currently, no specific prophylactic and therapeutic treatment is available. No evidence from randomized clinical trials (RCTs) that a treatment may ameliorate the clinical outcome of patients with COVID-19 exists with the only exception of preliminary evidence from remdesivir trials. Here, we present evidence from the literature and a compelling hypothesis on the potential immunomodulatory, iron chelating and anti-oxidant effects of iron chelators in the treatment of COVID-19 and its complications. Interestingly, iron chelation has been shown in vitro to suppress endothelial inflammation in viral infection, which is the main pathophysiologic mechanism behind systemic organ involvement induced by SARS-CoV-2, by inhibiting IL-6 synthesis through decreasing NF-kB. Iron chelators exhibit iron chelating, antiviral and immunomodulatory effects in vitro and in vivo, particularly against RNA viruses. These agents could attenuate ARDS and help control SARS-CoV-2 via multiple mechanisms including: 1) inhibition of viral replication; 2) decrease of iron availability; 3) upregulation of B cells; 4) improvement of the neutralizing anti-viral antibody titer; 5) inhibition of endothelial inflammation and 6) prevention of pulmonary fibrosis and lung decline via reduction of pulmonary iron accumulation. Both retrospective analyses of data in electronic health records, as well as proof of concept studies in humans and large RCTs are needed to fully elucidate the efficacy and safety of iron chelating agents in the therapeutic armamentarium of COVID-19, probably as an adjunctive treatment.","Metabolism","Dalamaga, Maria","Karampela, Irene","Mantzoros, Christos S","32418885"],"abstract":["The pandemic of COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses a significant threat to global health. Currently, no specific prophylactic and therapeutic treatment is available. No evidence from randomized clinical trials (RCTs) that a treatment may ameliorate the clinical outcome of patients with COVID-19 exists with the only exception of preliminary evidence from remdesivir trials. Here, we present evidence from the literature and a compelling hypothesis on the potential immunomodulatory, iron chelating and anti-oxidant effects of iron chelators in the treatment of COVID-19 and its complications. Interestingly, iron chelation has been shown in vitro to suppress endothelial inflammation in viral infection, which is the main pathophysiologic mechanism behind systemic organ involvement induced by SARS-CoV-2, by inhibiting IL-6 synthesis through decreasing NF-kB. Iron chelators exhibit iron chelating, antiviral and immunomodulatory effects in vitro and in vivo, particularly against RNA viruses. These agents could attenuate ARDS and help control SARS-CoV-2 via multiple mechanisms including: 1) inhibition of viral replication; 2) decrease of iron availability; 3) upregulation of B cells; 4) improvement of the neutralizing anti-viral antibody titer; 5) inhibition of endothelial inflammation and 6) prevention of pulmonary fibrosis and lung decline via reduction of pulmonary iron accumulation. Both retrospective analyses of data in electronic health records, as well as proof of concept studies in humans and large RCTs are needed to fully elucidate the efficacy and safety of iron chelating agents in the therapeutic armamentarium of COVID-19, probably as an adjunctive treatment."],"journal":"Metabolism","authors":["Dalamaga, Maria","Karampela, Irene","Mantzoros, Christos S"],"date":"2020-05-19T11:00:00Z","year":2020,"_id":"32418885","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.metabol.2020.154260","keywords":["ards","covid-19","coronavirus","deferoxamine","endotheliitis","heme","iron","iron chelator","pulmonary fibrosis"],"locations":["vivo"],"e_drugs":["remdesivir","Iron"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1667254896801349633,"score":217.19576},{"pmid":32376394,"title":"Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: A comprehensive review.","text":["Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: A comprehensive review.","Severe Acute Respiratory Syndrome related to Coronavirus-2 (SARS-CoV-2), coronavirus disease-2019 (COVID-19) may cause severe illness in 20% of patients. This may be in part due to an uncontrolled immune-response to SARS-CoV-2 infection triggering a systemic hyperinflammatory response, the so-called \"cytokine storm\". The reduction of this inflammatory immune-response could be considered as a potential therapeutic target against severe COVID-19. The relationship between inflammation and clot activation must also be considered. Furthermore, we must keep in mind that currently, no specific antiviral treatment is available for SARS-CoV-2. While moderate-severe forms need in-hospital surveillance plus antivirals and/or hydroxychloroquine; in severe and life-threating subsets a high intensity anti-inflammatory and immunomodulatory therapy could be a therapeutic option. However, right data on the effectiveness of different immunomodulating drugs are scarce. Herein, we discuss the pathogenesis and the possible role played by drugs such as: antimalarials, anti-IL6, anti-IL-1, calcineurin and JAK inhibitors, corticosteroids, immunoglobulins, heparins, angiotensin-converting enzyme agonists and statins in severe COVID-19.","Autoimmun Rev","Alijotas-Reig, Jaume","Esteve-Valverde, Enrique","Belizna, Cristina","Selva-O'Callaghan, Albert","Pardos-Gea, Josep","Quintana, Angela","Mekinian, Arsene","Anunciacion-Lunell, Ariadna","Miro-Mur, Francesc","32376394"],"abstract":["Severe Acute Respiratory Syndrome related to Coronavirus-2 (SARS-CoV-2), coronavirus disease-2019 (COVID-19) may cause severe illness in 20% of patients. This may be in part due to an uncontrolled immune-response to SARS-CoV-2 infection triggering a systemic hyperinflammatory response, the so-called \"cytokine storm\". The reduction of this inflammatory immune-response could be considered as a potential therapeutic target against severe COVID-19. The relationship between inflammation and clot activation must also be considered. Furthermore, we must keep in mind that currently, no specific antiviral treatment is available for SARS-CoV-2. While moderate-severe forms need in-hospital surveillance plus antivirals and/or hydroxychloroquine; in severe and life-threating subsets a high intensity anti-inflammatory and immunomodulatory therapy could be a therapeutic option. However, right data on the effectiveness of different immunomodulating drugs are scarce. Herein, we discuss the pathogenesis and the possible role played by drugs such as: antimalarials, anti-IL6, anti-IL-1, calcineurin and JAK inhibitors, corticosteroids, immunoglobulins, heparins, angiotensin-converting enzyme agonists and statins in severe COVID-19."],"journal":"Autoimmun Rev","authors":["Alijotas-Reig, Jaume","Esteve-Valverde, Enrique","Belizna, Cristina","Selva-O'Callaghan, Albert","Pardos-Gea, Josep","Quintana, Angela","Mekinian, Arsene","Anunciacion-Lunell, Ariadna","Miro-Mur, Francesc"],"date":"2020-05-08T11:00:00Z","year":2020,"_id":"32376394","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/j.autrev.2020.102569","keywords":["acute respiratory distress syndrome","covid-19","cytokine storm","immunosuppressive","sars-cov-2","treatment"],"e_drugs":["Hydroxychloroquine","Heparin"],"topics":["Treatment"],"weight":1,"_version_":1666597097290334208,"score":214.26724}]}